Psilocybin and Cannabinoid Combination for Brain Disorder Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for psychological and brain disorders often result in significant side effects and do not effectively address the underlying symptoms of depression, schizophrenia, anxiety disorders, and other related conditions.
Innovation Solution
Combining psilocybin and/or psilocin with at least one cannabinoid and/or terpene, where the cannabinoid and/or terpene can be administered separately, sequentially, or simultaneously, to provide a therapeutic regimen for the prevention or treatment of these disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for psychological and brain disorders are used, then treatment coverage is provided, but significant side effects occur and underlying symptoms are not effectively addressed
Solution Approach 1:
The patent combines psilocybin/psilocin with cannabinoids and/or terpenes into a single therapeutic composition. This merging of multiple active compounds with different mechanisms of action creates a synergistic effect that enhances treatment effectiveness for psychological disorders while potentially reducing the need for high doses of individual substances, thereby addressing the contradiction between treatment reliability and harmful side effects
Solution Approach 2:
The invention uses a composite therapeutic formulation containing psilocybin or psilocin in combination with one or more cannabinoids and/or terpenes. This composite approach leverages the complementary pharmacological properties of each component to achieve superior therapeutic outcomes compared to monotherapy, resolving the technical contradiction by providing both enhanced effectiveness and improved safety profile
2Reliability
If current treatments address symptoms, then immediate relief is provided, but underlying symptoms and progression of disorders are not effectively prevented
Solution Approach 1:
The patent employs psilocybin/psilocin in combination with cannabinoids and/or terpenes to produce lasting therapeutic effects that prevent disease progression before symptoms can worsen. The combination formulation acts on multiple neurological pathways simultaneously, creating sustained therapeutic benefits that address both current symptoms and prevent future episodes, thereby resolving the contradiction between immediate symptom management and long-term disease prevention
Data Source
AI summary
The present invention relates to the use of one or more cannabinoids and/or terpenes in combination with psilocybin and/or psilocin for use in the prevention or treatment of psychological or brain disorders. Preferably the one or more cannabinoids are taken from the group cannabidiol (CBD); cannabidiolic acid (CBDA); tetrahydrocannbidivarin (THCV); tetrahydrocannbidivarinin acid (THCVA); cannabichromene (CBC); cannabichromenic acid (CBCA); cannabigerol (CBG) and cannabigerolic acid (CBGA).